Acute pharmacotherapy of migraine, tension-type headache, and cluster headache

Tfelt‐Hansen, Peer

doi:10.1007/s10194-007-0373-z

Cited by 12 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, migraine treatment can be carried out with triptans and ergot derivatives and NSAIDs. There is no specific therapy for TTH and as a consequence, NSAIDs represent the only treatment [Tfelt-Hansen, 2007]. A communitybased telephone survey [Forward et al, 1998] reported that 98% of TTH sufferers depend on NSAIDs.…”

Section: Nsaids Role In the Acute Treatment Of Headachementioning

confidence: 99%

Role of NSAIDs in acute treatment of headache

Martelletti¹,

Farinelli²,

Coloprisco³

et al. 2007

Drug Development Research

View full text Add to dashboard Cite

Headache is one of the most common neurological disorders worldwide. Tension-type headache (TTH) represents the most frequent headache form, involving 82% of sufferers. Of this population, 14% are affected by migraine and 4% by a chronic form of headache (chronic daily headache [CDH]). Nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most used acute therapy for TTH and migraine because of issues with coxibs safety. NSAIDs play a minor role is the treatment in trigeminal-autonomic cephalgias (TACs); if excluding indomethacin in the acute management of paroxysmal hemicrania (PH). Despite limitations in their utilization, NSAIDs still constitute drugs of primary importance, being effective and being well tolerated in the treatment of acute episodes. © 2007 Wiley-Liss, Inc

show abstract

Section: Nsaids Role In the Acute Treatment Of Headachementioning

confidence: 99%

Role of NSAIDs in acute treatment of headache

Martelletti¹,

Farinelli²,

Coloprisco³

et al. 2007

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…In attempts to provide greater efficacy than oral administration and more convenience than SC injection, several other routes of administration for migraine medications have been developed: intranasal (late 1997), orally dissolving tablets (1998), transdermal sumatriptan (2012), bi‐directional intranasal sumatriptan (investigatory), and inhaled dihydroergotamine (investigatory) . Regardless, SC sumatriptan remains the most effective and fastest acting of the available treatment options, with higher reported rates of 2‐hour pain relief and pain freedom than the various other formulations of sumatriptan available (Table ) …”

Section: History Of Needle‐free Sumatriptan Injection In Migraine Thementioning

confidence: 99%

A Review of Needle‐Free Sumatriptan Injection for Rapid Control of Migraine

et al. 2013

View full text Add to dashboard Cite

The treatment of migraine was transformed in 1992 with the introduction of the first triptan-based therapy, subcutaneous (SC) sumatriptan. SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance of enteral absorption. Because of these characteristics, SC sumatriptan is still considered the most reliably and rapidly effective self-administered medication available for acute migraine. Even so, it is relatively little used possibly in part because of patient "needle-phobia." The needle-free sumatriptan injection system (Sumavel DosePro) was developed to address this concern. Clinical trials have shown that the needle-free system is bioequivalent to needle-based injection systems, easy to use, and capable of providing rapid and effective symptom relief for many migraine episodes. Sumavel DosePro is an effective treatment for migraine and should be part of the therapeutic armamentarium, particularly in cases where a rapid onset of action is critical or where oral administration is problematic.

show abstract

“…Sumatriptan constitutes the archetype of a new class of specific molecules with abortive action, namely triptans, which have now reached their seventh molecule. At present, nonsteriodal anti-inflammatory drugs (NSAIDs) still represent the most common drugs used in acute migraine therapy [5,6].…”

Section: Introductionmentioning

confidence: 99%

Future drugs for migraine

et al. 2009

View full text Add to dashboard Cite

Migraine is a complex, neurovascular disorder in which genetic and environmental factors interact. At present, frontline therapies in the acute treatment of migraine include the use of non-steroidal anti-inflammatory drugs and triptans. Evidence indicates that calcitonin gene-related peptide (CGRP) plays a fundamental role in the mechanism of migraine. CGRP is a strong vasodilatatory neuropeptide that is released from activated trigeminal sensory nerves. The development of CGRP antagonists has also been driven by the fact that triptans are vasoconstrictive and cannot be safely used in patients with cardiovascular risk factors. Olcegepant (BIBN4096) is the first CGRP antagonist for the treatment of migraine that has been tested in clinical trials, but because of its poor oral bioavailability, only the intravenous formulation has been tested. The first oral non-peptide CGRP antagonist, telcagepant, has been shown recently to be highly effective in the treatment of migraine attacks. This development can be considered as the most important pharmacological breakthrough for migraine treatment since the introduction of sumatriptan in the early 1990s. These results are also of importance, since they support an interesting pathophysiological hypothesis of migraine. The pipeline of future compounds for the treatment of acute migraine headaches include TPRV1 antagonists, prostaglandin E receptor 4 (EP(4)) receptor antagonists, serotonin 5HT1(F) receptor agonists and nitric oxide synthase inhibitors. The immediate future of a preventative treatment for migraine headaches is well represented by botulinum toxin type-A, glutamate NMDA receptor antagonists, gap-junction blocker tonabersat and an angiotensin type 1 blocker candesartan.

show abstract

Acute pharmacotherapy of migraine, tension-type headache, and cluster headache

Cited by 12 publications

References 45 publications

Role of NSAIDs in acute treatment of headache

Role of NSAIDs in acute treatment of headache

A Review of Needle‐Free Sumatriptan Injection for Rapid Control of Migraine

Future drugs for migraine

Contact Info

Product

Resources

About